480 related articles for article (PubMed ID: 15998902)
1. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).
Tinker AV; Ellard S; Welch S; Moens F; Allo G; Tsao MS; Squire J; Tu D; Eisenhauer EA; MacKay H
Gynecol Oncol; 2013 Aug; 130(2):269-74. PubMed ID: 23672928
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
Schiff D; Jaeckle KA; Anderson SK; Galanis E; Giannini C; Buckner JC; Stella P; Flynn PJ; Erickson BJ; Schwerkoske JF; Kaluza V; Twohy E; Dancey J; Wright J; Sarkaria JN
Cancer; 2018 Apr; 124(7):1455-1463. PubMed ID: 29313954
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
Chang SM; Wen P; Cloughesy T; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; De Angelis L; Raizer J; Hess K; Aldape K; Lamborn KR; Kuhn J; Dancey J; Prados MD;
Invest New Drugs; 2005 Aug; 23(4):357-61. PubMed ID: 16012795
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
[TBL] [Abstract][Full Text] [Related]
9. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
Busaidy NL; LoRusso P; Lawhorn K; Hess KR; Habra MA; Fu S; Hong DS; Chen HX; Doyle LA; Kurzrock R; Naing A
Oncologist; 2015 Jul; 20(7):737-41. PubMed ID: 26054632
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
Lee EQ; Kuhn J; Lamborn KR; Abrey L; DeAngelis LM; Lieberman F; Robins HI; Chang SM; Yung WK; Drappatz J; Mehta MP; Levin VA; Aldape K; Dancey JE; Wright JJ; Prados MD; Cloughesy TF; Gilbert MR; Wen PY
Neuro Oncol; 2012 Dec; 14(12):1511-8. PubMed ID: 23099651
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
Galanis E; Jaeckle KA; Maurer MJ; Reid JM; Ames MM; Hardwick JS; Reilly JF; Loboda A; Nebozhyn M; Fantin VR; Richon VM; Scheithauer B; Giannini C; Flynn PJ; Moore DF; Zwiebel J; Buckner JC
J Clin Oncol; 2009 Apr; 27(12):2052-8. PubMed ID: 19307505
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
Kaley TJ; Panageas KS; Pentsova EI; Mellinghoff IK; Nolan C; Gavrilovic I; DeAngelis LM; Abrey LE; Holland EC; Omuro A; Lacouture ME; Ludwig E; Lassman AB
Ann Clin Transl Neurol; 2020 Apr; 7(4):429-436. PubMed ID: 32293798
[TBL] [Abstract][Full Text] [Related]
16. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
[TBL] [Abstract][Full Text] [Related]
18. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
[TBL] [Abstract][Full Text] [Related]
19. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.
Sarkaria JN; Galanis E; Wu W; Dietz AB; Kaufmann TJ; Gustafson MP; Brown PD; Uhm JH; Rao RD; Doyle L; Giannini C; Jaeckle KA; Buckner JC
Clin Cancer Res; 2010 Nov; 16(22):5573-80. PubMed ID: 20921209
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]